文献速递前列腺癌

达罗他胺联合ADT在前列腺特异性抗原深度应答与临床结局的关联:ARANOTE 3期试验

A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2025-08-22

ARANOTE试验纳入转移性激素敏感性前列腺癌患者,随机接受达罗他胺600mg每日两次或安慰剂联合ADT。达罗他胺组PSA<0.2 ng/ml和<0.02 ng/ml达成率分别为63% vs 18%和43% vs 7.8%,且PSA深度应答与rPFS、OS、mCRPC时间及PSA进展时间改善显著相关。

要点

  • 达罗他胺组PSA<0.2 ng/ml达成率是安慰剂组的3倍(63% vs 18%)。
  • PSA<0.2 ng/ml者rPFS风险比0.19,OS风险比0.14,临床获益显著。
  • 达到超低PSA(<0.02 ng/ml)的患者从达罗他胺中获益最大。

核心结论

  • 达罗他胺带来深度且持久的PSA应答,不受基线PSA影响。
  • 深度PSA应答与更好的临床结局相关,超低PSA者临床获益最大。

研究设计与样本

  • ARANOTE(NCT04736199)3期随机试验,转移性激素敏感性前列腺癌患者随机接受达罗他胺600 mg每日两次或安慰剂联合ADT。
  • 事后分析采用非分层Cox回归模型评估PSA应答与临床结局的相关性。

主要发现

  • 达罗他胺组任意时间PSA<0.2 ng/ml达成率为63% vs 安慰剂组18%,PSA<0.02 ng/ml为43% vs 7.8%。
  • 根据基线PSA,达罗他胺组高达88%患者达到不可测PSA,高达69%达到超低PSA。
  • PSA<0.2 ng/ml vs ≥0.2 ng/ml的rPFS风险比0.19(95%CI 0.13-0.27),OS风险比0.14(95%CI 0.09-0.21)。
  • mCRPC时间风险比0.16(95%CI 0.12-0.23),PSA进展时间风险比0.08(95%CI 0.05-0.12)。

关键数值与推荐

  • PSA<0.2 ng/ml和<0.02 ng/ml达成率在达罗他胺组分别为63%和43%,安慰剂组为18%和7.8%。
  • PSA<0.2 ng/ml者rPFS、OS、mCRPC时间、PSA进展时间的风险比分别为0.19、0.14、0.16、0.08。

临床怎么用

  • 达罗他胺联合ADT治疗转移性激素敏感性前列腺癌时,应监测PSA应答深度。
  • 达到PSA<0.2 ng/ml尤其<0.02 ng/ml提示更好的临床结局,可辅助临床决策。

局限性

  • PSA应答与临床结局的相关性为事后分析,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Darolutamide plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) versus ADT in ARANOTE (NCT04736199). Here we report prostate-specific antigen (PSA) responses and their correlation with clinical outcomes. METHODS: Patients with metastatic hormone-sensitive prostate cancer were randomized to darolutamide 600 mg twice daily or placebo plus ADT. The proportion of patients achieving undetectable PSA (<0.2 ng/ml) and ultra-low PSA (<0.02 ng/ml) were determined overall and by baseline PSA category. A post hoc analysis was conducted to identify any correlation of rPFS, overall survival (OS), time to metastatic castration-resistant prostate cancer (mCRPC), and time to PSA progression with PSA responses and baseline PSA using an unstratified Cox regression model. KEY FINDINGS AND LIMITATIONS: The rate of achievement of PSA <0.2 ng/ml and of PSA <0.02 ng/ml at any time was threefold greater (63% vs 18%) and fivefold greater (43% vs 7.8%), respectively, in the darolutamide arm versus the placebo arm, with a consistent effect across baseline PSA subgroups. Depending on baseline PSA, up to 88% of patients treated with darolutamide achieved undetectable PSA and up to 69% achieved ultra-low PSA. Achievement of PSA <0.2 ng/ml versus ≥0.2 ng/ml was associated with much better rPFS, OS, time to mCRPC, and PSA progression, with hazard ratios of 0.19 (95% confidence interval [CI] 0.13-0.27), 0.14 (95% CI 0.09-0.21), 0.16 (95% CI 0.12-0.23), and 0.08 (95% CI 0.05-0.12), respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: Darolutamide resulted in deep and durable PSA responses, regardless of baseline PSA. A deep PSA response was associated with better clinical outcomes, and patients reaching ultra-low PSA had the greatest clinical benefits from darolutamide.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Saad F, Briganti A, Haresh KP, et al. A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40846621. doi:10.1016/j.euo.2025.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。